BioMarin Pharmaceutical: Morgan Stanley cuts target price to $119 from $122
BMRN•Morgan Stanley cut its target price for BioMarin Pharmaceutical to $119 from $122.
Related News
Oracle tumbles on $20 bln stock-and-bonds sale to fund AI ambitions
ORCL•
Adeia slides after lowering annual forecast
ADEA•
Match Group: Deutsche Bank raises target price to $50 from $45
MTCH•
Onsemi: Rosenblatt Securities cuts target price to $80 from $85
ON•
Northland Capital raises Palantir target price to $210 from $200
PLTR•